Reumatoloxía
Servicio
Federico
Díaz González
Publicacións nas que colabora con Federico Díaz González (33)
2024
-
Early identification of golimumab-treated patients with higher likelihood of long-term retention
Frontiers in Immunology, Vol. 15
-
The complement system is linked to insulin resistance in patients with systemic lupus erythematosus
Clinical and experimental rheumatology, Vol. 42, Núm. 1, pp. 115-121
2023
-
Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
RMD open, Vol. 9, Núm. 1
-
Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases
Advances in Rheumatology, Vol. 63, Núm. 1
-
Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus
Frontiers in Immunology, Vol. 14
-
HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
Journal of Clinical Medicine, Vol. 12, Núm. 16
-
Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis
Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197
2022
-
Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables
Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096
2021
-
Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
Scientific Reports, Vol. 11, Núm. 1
-
Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply
Rheumatology (Oxford, England), Vol. 60, Núm. 3, pp. e120-e121
-
Differences in Capacity of High-Density Lipoprotein Cholesterol Efflux Between Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
Arthritis Care and Research, Vol. 73, Núm. 11, pp. 1590-1596
-
Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry
Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988
-
Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study
Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470
-
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study
RMD Open, Vol. 7, Núm. 3
-
Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs
Reumatologia Clinica, Vol. 17, Núm. 3, pp. 160-169
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
-
Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study
Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170
-
Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: Data from the BIOBADASER III register
Arthritis Research and Therapy, Vol. 22, Núm. 1
-
Prevalence of systemic lupus erythematosus in Spain: Higher than previously reported in other countries?
Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2556-2562
-
The prevalence of rheumatoid arthritis in Spain
Scientific Reports, Vol. 10, Núm. 1